140 related articles for article (PubMed ID: 30423862)
1. Radiobiological Characterization of
Guerreiro JF; Alves V; Abrunhosa AJ; Paulo A; Gil OM; Mendes F
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423862
[No Abstract] [Full Text] [Related]
2. 64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?
Cantiello F; Crocerossa F; Cascini GL; Russo GI; Ferro M; Cimino S; Lucarelli G; Damiano R
Minerva Urol Nephrol; 2021 Oct; 73(5):668-671. PubMed ID: 32182228
[TBL] [Abstract][Full Text] [Related]
3. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
4. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
7. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer.
Xiang J; Bian C; Wang H; Huang S; Wu D
J Exp Clin Cancer Res; 2015 Jan; 34(1):8. PubMed ID: 25636908
[TBL] [Abstract][Full Text] [Related]
8. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Yoshii Y; Furukawa T; Matsumoto H; Yoshimoto M; Kiyono Y; Zhang MR; Fujibayashi Y; Saga T
Cancer Lett; 2016 Jun; 376(1):74-82. PubMed ID: 26996296
[TBL] [Abstract][Full Text] [Related]
9. Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer.
Pinto CIG; Bucar S; Alves V; Fonseca A; Abrunhosa AJ; da Silva CL; Guerreiro JF; Mendes F
Front Mol Biosci; 2020; 7():609172. PubMed ID: 33335914
[TBL] [Abstract][Full Text] [Related]
10. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
Kong Z; Raghavan P; Xie D; Boike T; Burma S; Chen D; Chakraborty A; Hsieh JT; Saha D
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1210-8. PubMed ID: 20970033
[TBL] [Abstract][Full Text] [Related]
11. The biological functions and mechanism of miR‑212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
Zhou Y; Ji Z; Yan W; Zhou Z; Li H
Oncol Rep; 2017 Sep; 38(3):1411-1419. PubMed ID: 28713997
[TBL] [Abstract][Full Text] [Related]
12. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
13. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
[TBL] [Abstract][Full Text] [Related]
15. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
[TBL] [Abstract][Full Text] [Related]
16. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.
Green SM; Kaipainen A; Bullock K; Zhang A; Lucas JM; Matson C; Banks WA; Mostaghel EA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):20-27. PubMed ID: 27645128
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
18. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
19. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
20. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Angelucci A; Gravina GL; Rucci N; Millimaggi D; Festuccia C; Muzi P; Teti A; Vicentini C; Bologna M
Endocr Relat Cancer; 2006 Mar; 13(1):197-210. PubMed ID: 16601288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
